UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 000-41218 Zapata Quantum, Inc. (Exact name of registrant as specified in charter) (State or other jurisdiction of incorpora ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 000-41218 Zapata Quantum, Inc. (Exact name of registrant as specified in charter) Delaware 98-1578373 (State or ot ...

Financial Performance - Net sales for the three months ended October 31, 2025, were $47.6 million, an increase of $1.8 million or 4.0% compared to $45.8 million for the same period in 2024[126]. - Net sales for the nine months ended October 31, 2025, were $146.8 million, an increase of 21.8% from $120.6 million for the same period in 2024, driven by acquisitions and organic growth[133]. - Net loss for the three months ended October 31, 2025, was $(16.0) million, compared to net income of $0.1 million for the same period in 2024[132]. Gross Profit and Operating Loss - Gross profit for the three months ended October 31, 2025, was $14.1 million, a decrease of $4.5 million or 23.9% compared to $18.6 million for the same period in 2024, with gross profit as a percentage of net sales decreasing to 29.7% from 40.6%[127]. - Gross profit for the nine months ended October 31, 2025, was $48.6 million, a decrease of $1.4 million or 2.8% from $50.0 million in 2024, with gross profit margin dropping to 33.1% from 41.4%[134]. - Operating loss for the nine months ended October 31, 2025, was $(10.3) million, compared to operating income of $1.4 million for the same period in 2024, resulting in an operating margin of (7.0%)[138]. Operating Expenses - Operating expenses increased by $2.3 million or 13.1% to $20.1 million for the three months ended October 31, 2025, primarily due to acquisitions and increased stock-based compensation[128]. - Operating expenses increased by $11.1 million or 22.8% to $59.6 million for the nine months ended October 31, 2025, with operating expenses as a percentage of net sales rising to 40.6%[135]. Income Tax Expense - Income tax expense for the three months ended October 31, 2025, was $13.7 million, significantly higher than $0.1 million for the same period in 2024, resulting in an effective tax rate of (597.9%)[131]. - Income tax expense for the nine months ended October 31, 2025, was $7.3 million, compared to $0.1 million for the same period in 2024[139]. Acquisitions - The company acquired Arizona PPE for approximately $4.1 million and California PPE for a combination of $2.4 million in cash and $3.3 million in stock in September 2025[118][119]. - The company also acquired Veridian for approximately $26.1 million in December 2024, which had an annual revenue of approximately $21.0 million[120]. Cash Flow and Liquidity - Cash and cash equivalents as of October 31, 2025, were approximately $17.2 million, with a decrease of $0.3 million from January 31, 2025[142]. - Cash used in operations was $17.6 million due to a net loss of $(19.1) million and an increase in working capital of $7.9 million[144]. - The Company expects its current cash, cash equivalents, and borrowing capacity to meet projected operating and investing requirements for at least the next twelve months[145]. Sales by Region - Net sales attributable to customers outside the U.S. were $28.4 million for the three months ended October 31, 2025, compared to $30.4 million for the same period in 2024[123]. - Sales in Russia accounted for approximately 2.2% of consolidated sales for the nine months ended October 31, 2025, with no significant sales in Ukraine[125]. Cost Challenges - The company is facing increased costs due to tariffs and higher manufacturing costs, which are expected to continue affecting operating results and margins[124].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the quarterly period ended October 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-42434 ServiceTitan, Inc. (Exact name of registrant as specified in its charter) Delaware 26-0331862 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Casey's General Stores, Inc. One SE Convenience Blvd Ankeny, IA 50021 Casey's Announces Second Quarter Results Ankeny, IA, December 9, 2025 - Casey's General Stores, Inc. ("Casey's" or the "Company") (Nasdaq: CASY) one of the leading convenience store chains in the United States, today announced financial results for the three and six months ended October 31, 2025. Second Quarter Key Highlights "Casey's delivered a great second quarter highlighted by strong sales and traff ...

Store Operations and Growth - As of October 31, 2025, Casey's operates 2,921 stores, with approximately 71% located in areas with populations under 20,000[56] - The Fikes acquisition added 198 stores and a wholesale fuel network, contributing $511,805 to total revenue for the second quarter of fiscal 2026, which increased by $559,313 (14.2%) year-over-year[55][69] - Operating expenses increased by $101,908 (16.7%) to $711,587, with approximately 10.5% of the increase attributed to operating 236 more stores[73] - Total revenue for the first six months of fiscal 2026 increased by $1,028,682 (12.8%) compared to the same period in fiscal 2025, primarily driven by $1,034,139 from the Fikes acquisition[78] - Prepared food and dispensed beverage revenue rose by $103,277 (12.5%) due to a 5.0% increase in same-store sales and approximately 7.5% from store growth[78] - Grocery and general merchandise revenue increased by $297,348 (14.0%), with a 10.8% contribution from store growth and a 3.2% increase in same-store sales[78] - Retail fuel revenue grew by $450,674 (9.1%), supported by an increase of 269,982 gallons sold (17.4%), despite a 7.1% decrease in average retail price per gallon[78] - Other revenue surged by $177,383 (133.8%) primarily due to increased wholesale fuel revenue from the Fikes acquisition[79] - Operating expenses increased by $190,610 (15.6%), with 236 more stores accounting for approximately 10% of the increase[83] Financial Performance - Net income rose by $25,418 (14.0%) to $206,336, driven by higher profitability in-store and in fuel[77] - Net income rose by $60,575 (16.8%) to $421,691, attributed to higher profitability in stores and fuel, offset by increased operating expenses[86] - EBITDA for the first six months of fiscal 2026 increased by 18.7% to $824,369 compared to $694,662 in the prior year[89] - The effective tax rate decreased to 23.7% from 24.3% in the prior year, mainly due to increased excess tax benefits from share-based awards[85] - Net cash provided by operating activities was $719,486, an increase of $167,429 from the prior year, driven by improved revenue less cost of goods sold[94] Debt and Interest Expenses - Interest expense increased by $12,137 (96.7%) to $24,690, primarily due to incremental debt issued to fund the Fikes acquisition[76] - As of October 31, 2025, the Company had total long-term debt of $2,352,032,000 after accounting for current maturities and debt issuance costs[97] - The Company has a total of $818,125,000 in variable rate incremental term loan facilities, requiring quarterly installments until October 30, 2029[97] - The Company has issued various senior notes with interest rates ranging from 2.85% to 5.43%, with total amounts due across different maturities[97] - An immediate 100-basis-point increase in interest rates would result in an approximate annualized impact of $9.6 million on interest expense[105] Strategic Initiatives and Environmental Commitment - As of October 31, 2025, Casey's has 232 EV charging stations at 48 stores across 13 states, reflecting the company's commitment to an electric vehicle strategy[64] - Approximately 41% of stores offer biodiesel, and all newly built stores are equipped to sell renewable fuels, aligning with the company's environmental stewardship efforts[65] - The Company has a strategy focused on identifying, acquiring, and integrating new properties and stores to support business growth[102] Risks and Regulatory Environment - The Company emphasizes that its financial condition may be adversely affected by increases in food ingredient costs and disruptions in the distribution network[99] - The Company is subject to extensive governmental regulations that could materially impact revenues and gross profit, particularly in the tobacco and nicotine sectors[100] - The Company faces risks related to changes in consumer preferences and the need for innovative technology to maintain financial performance[99] Cost Management and Revenue Analysis - Total revenue less cost of goods sold (exclusive of depreciation and amortization) was 24.9% of revenue for the second quarter of fiscal 2026, compared to 24.3% in the prior year[71] - Fuel revenue less cost of goods sold (exclusive of depreciation and amortization) increased to 14.0% of fuel revenue, with revenue less cost of goods sold per gallon rising to 41.6 cents[72] - The Company utilizes futures contracts to hedge against fuel price volatility, ensuring that all hedges are matched against recorded physical transactions[106]

Product Development - The company has developed two product candidates, AL001 and ALZN002, targeting Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder[103]. - AL001, an ionic cocrystal of lithium, has shown superior results in preclinical studies, preventing cognitive deficits and improving memory compared to traditional lithium carbonate treatments[109]. - A Phase IIA clinical trial for AL001 was completed in March 2023, with positive topline data announced in June 2023, and full data expected in October 2024[110]. - The maximum tolerated dose for AL001 was identified as 240 mg three times daily, designed to mitigate risks for fragile populations like Alzheimer's patients[111]. - The company plans to initiate five clinical trials to compare lithium levels in the brain between AL001 and marketed lithium salts, with a partnership established with Massachusetts General Hospital for these trials[115]. - ALZN002 is an active immunotherapy vaccine designed to treat mild to moderate Alzheimer's dementia, with a Phase I/IIA clinical trial initiated in April 2023[120][121]. - The company has received a "study may proceed" letter from the FDA for ALZN002, indicating regulatory progress for this product candidate[120]. - AL001's formulation aims to reduce systemic toxicity and improve brain bioavailability, potentially offering a safer long-term treatment option for patients[118]. Financial Performance - For the three months ended October 31, 2025, total operating expenses decreased by 27% to $998,109 from $1,358,068 in 2024[124]. - Research and development expenses for the three months ended October 31, 2025, were $176,283, a decrease of 43% from $311,088 in 2024[126]. - General and administrative expenses for the three months ended October 31, 2025, were $821,826, down 22% from $1,046,980 in 2024[130]. - The net loss for the three months ended October 31, 2025, was $1,000,758, a reduction of 26% compared to a net loss of $1,361,563 in 2024[124]. - For the six months ended October 31, 2025, research and development expenses surged by 270% to $1.9 million from $518,000 in 2024[139]. - Clinical trial fees for the six months ended October 31, 2025, increased significantly to $1.7 million from $124,000 in 2024, reflecting a 1,270% rise[141]. - The company did not generate any revenue during the three months ended October 31, 2025, and does not anticipate generating revenue in the foreseeable future[125]. - Basic and diluted net loss per common share improved to $(0.30) for the three months ended October 31, 2025, from $(3.61) in 2024[124]. - Total general and administrative expenses for the six months ended October 31, 2025, were $1.8 million, consistent with the previous year[143]. - The company incurred no marketing fees for the three months ended October 31, 2025, compared to $304,000 in 2024[136]. - Professional fees increased to $712,000 in the six months ended October 31, 2025, from $371,000 in the same period of 2024, primarily due to higher legal fees related to the termination of the ALZN002 clinical trial[146][147]. - Insurance expenses decreased to $118,000 in the six months ended October 31, 2025, compared to $139,000 in the same period of 2024[148]. - Stock-based compensation expense decreased to $74,000 in the six months ended October 31, 2025, from $163,000 in the same period of 2024, due to fewer stock options vesting[149]. - Marketing fees decreased to $150,000 in the six months ended October 31, 2025, from $344,000 in the same period of 2024[150]. - As of October 31, 2025, the company had cash of $4.4 million, working capital of $4.0 million, and an accumulated deficit of $62.2 million[152]. - The company reported net losses of $1.0 million and $3.7 million for the three and six months ended October 31, 2025, respectively[152]. - Net cash used in operating activities was $3.5 million for the six months ended October 31, 2025, primarily due to a net loss of $3.7 million[157]. - Net cash provided by financing activities was $4.0 million from the sale of Series C Convertible Preferred Stock during the six months ended October 31, 2025[159]. - The company will need to obtain substantial additional funding for clinical development activities and continuing operations[153]. Licensing and Royalties - Royalty payments for the AL001 License Agreements are set at 4.5% on net sales, with minimum royalties starting at $40,000 on the first anniversary of the first commercial sale[161].

Financial Performance - Total revenue for the first quarter decreased by 5.7% compared to the same period in the prior year, amounting to $797,188,000[98]. - Comparable store restaurant sales decreased by 4.7%, while comparable store retail sales decreased by 8.5%[99]. - Operating income for the quarter was a loss of 4.1% of total revenue, compared to a gain of 0.8% in the prior year[97]. - Operating loss for the first quarter of 2026 was $(32,797), a significant decline from operating income of $7,071 in the same period of 2025, attributed to decreased total revenue and higher expenses[122]. - Net loss for the first quarter of 2026 was $(24,622), compared to net income of $4,844 in the prior year, primarily due to the operating loss[127]. - Cash used in operations was $53,430 in the first quarter of 2026, a substantial increase from $4,395 in the same period of 2025, driven by operating losses and timing of payments[130]. Cost and Expenses - The cost of goods sold increased to 31.2% of total revenue, up from 30.6% in the previous year[97]. - Labor and related expenses rose to 37.8% of total revenue, compared to 36.4% in the prior year[97]. - Other store operating expenses rose to 28.7% of total revenue in the first quarter of 2026, compared to 25.0% in the prior year, primarily due to increased occupancy and advertising costs[113]. - Labor and related expenses increased to 37.8% of total revenue in the first quarter of 2026, up from 36.4% in the same period of 2025, driven by higher store management compensation and hourly labor costs[108]. Strategic Initiatives - The company plans to refine its brand identity and enhance its menu offerings as part of its multi-year strategic plan[93]. - Negative publicity from recent brand initiatives contributed to a decrease in guest traffic, impacting overall sales[102]. Capital and Financing - Capital expenditures for the first quarter of 2026 were $34,165, down from $38,887 in the prior year, with expectations of $110,000 to $125,000 for the full year[131][132]. - The Company issued the 2030 Notes with a cash interest rate of 1.75% per annum, maturing on September 15, 2030, and net proceeds of approximately $335 million after fees[136]. - Approximately $145.9 million of the net proceeds from the 2030 Notes were used to repurchase $150 million of the 2026 Notes, which bear a cash interest rate of 0.625% per annum[137]. - The Company had negative working capital of $288.3 million as of October 31, 2025, an improvement from negative working capital of $312.5 million on August 1, 2025[144]. - Outstanding borrowings under the 2025 Revolving Credit Facility totaled $65 million as of October 31, 2025, with interest rate risk managed through a mix of fixed and variable rate debt[154]. - A one-percentage point change in the $65 million outstanding borrowings would impact pre-tax annualized costs by approximately $657[155]. Dividends and Share Repurchase - During the first three months of 2026, the Company paid a regular dividend of $0.25 per share and declared another dividend of $0.25 per share for payment on February 11, 2026[140]. - The Board of Directors approved a share repurchase authorization of up to $100 million, although no shares were repurchased in the first quarter of 2026[141]. Tax and Credit Risk - The effective tax rate for the first quarter of 2026 was 32.6%, an increase from (287.8)% in the prior year, primarily due to the benefit of employment credits in the previous period[124]. - The Company believes it does not have a material exposure to credit risk related to its Capped Call Transactions and Convertible Note Hedge Transactions at this time[156]. Store Operations - The number of Cracker Barrel locations decreased from 658 to 656, while Maple Street Biscuit Company locations decreased from 69 to 54[97]. - The company operates 656 Cracker Barrel stores in 43 states and 54 Maple Street Biscuit Company locations in ten states as of October 31, 2025[88].

Financial Performance - Revenues for Q3 fiscal 2026 were approximately $9.7 million, down 28.7% from $13.6 million in Q2 fiscal 2026 and down 19.5% from $12.1 million in Q3 fiscal 2025[2] - Operating income for Q3 fiscal 2026 was $774,000, a decrease of 71.5% from $2.7 million in Q2 fiscal 2026 and down 59.3% from $1.9 million in Q3 fiscal 2025[3] - Net income for Q3 fiscal 2026 was $62,000, compared to $1.9 million in Q2 fiscal 2026 and approximately $1.3 million in Q3 fiscal 2025, resulting in a net income per share of $0.01[3] - Adjusted EBITDA for Q3 fiscal 2026 was approximately $1.3 million, down 58.1% from $3.1 million in Q2 fiscal 2026 and down 35% from $2.0 million in Q3 fiscal 2025[4] - For the nine months ended October 31, 2025, net income was $1,021 million, a decrease from $3,043 million in the same period of 2024, representing a decline of approximately 66.5%[23] - EBITDA for the nine months ended October 31, 2025, was $3,355 million, down from $5,080 million in 2024, reflecting a decrease of about 34%[24] - Adjusted EBITDA for the nine months ended October 31, 2025, was $4,191 million, down from $5,221 million in 2024, reflecting a decrease of approximately 19.8%[24] Cash Flow and Working Capital - The company generated approximately $11.0 million in cash through its ATM program during the quarter, ending with nearly $36.0 million in working capital, of which $19.4 million was cash[7] - Net cash provided by operating activities for the nine months ended October 31, 2025, was $3,803 million, compared to a net cash used of $1,407 million in 2024, indicating a significant turnaround[23] - Cash and cash equivalents at the end of the period were $19,387 million, up from $3,505 million at the end of the same period in 2024, showing an increase of approximately 453%[23] - The company reported a net cash used in investing activities of $512 million for the nine months ended October 31, 2025, compared to a net cash provided of $244 million in 2024[23] Assets and Equity - Total current assets increased to $42.8 million as of October 31, 2025, compared to $32.1 million as of January 31, 2025[19] - Total stockholders' equity rose to $39.9 million as of October 31, 2025, up from $27.3 million as of January 31, 2025[19] Backlog and Future Expectations - The backlog of Marine Technology Products was approximately $7.2 million as of October 31, 2025, down from $12.8 million at July 31, 2025 and $26.2 million at October 31, 2024[5] - The company expects an improved fourth quarter based on the anticipated delivery schedule of its backlog and recent orders[6] Stock-Based Compensation and Foreign Exchange - Stock-based compensation for the nine months ended October 31, 2025, was $836 million, significantly higher than $141 million in 2024, marking an increase of about 493%[23] - The company experienced a foreign exchange rate effect of $6 million on cash and cash equivalents for the nine months ended October 31, 2025, compared to a negative effect of $2 million in 2024[23] Accounts Receivable Changes - Changes in accounts receivable for the nine months ended October 31, 2025, resulted in a cash inflow of $1,228 million, compared to a cash outflow of $3,006 million in 2024[23] Common Stock Issuance - The net proceeds from the issuance of common stock amounted to $10,754 million in the nine months ended October 31, 2025, while there were no proceeds in the same period of 2024[23]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 1, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-33338 American Eagle Outfitters, Inc. (Exact name of registrant as specified in its charter) Delaware No. 13-2721761 (State or other jurisdiction of incorporation or organi ...